Cephalosporin Drugs Market, By Generation (First-generation, Second-generation, Third-generation, Fourth-generation, and Fifth-generation), By Type (Branded and Generics), By Route of Drug Administration (Injection and Oral), and By Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, and Sexually Transmitted Infection), and By Region - Global Opportunity Analysis and Industry Forecast, 2020 – 2030

Cephalosporin Drugs Market size was valued at USD 12304.1 million in 2020 and is estimated to reach USD 16217.4 million by 2030, growing at a CAGR of 2.8% during the forecast period.Cephalosporins are a type of antibiotic commonly known as beta-lactam antibiotic. Cephalosporin was first prepared from a fungus named cephalosporium acremonium by scientist Dr. Abraham in 1948. A Cephalosporin Drugs is a group of semi-synthetic, wide-spectrum antibiotics mainly used to treat infections of bacteria. Cephalosporin Drugs are categorized based on the category of bacteria against which they are most efficient. Cephalosporin drugs are considered broad-spectrum antibiotics having similar activities to those of ampicillin and often are considered an alternative to penicillin for many patients. Cephalosporin drugs are used to treat infections in different parts of the body such as the lungs, ears, sinuses, nose, throat, and skin. Physicians also prescribe these drugs to treat pneumonia, staph infections, bronchitis, strep throat, tonsillitis, and gonorrhea. Various organizations around the world are taking initiatives to improve the development and delivery of antibiotic treatments. One such program is the Global Antibiotic Research and Development Partnership (GARDP), which is a not-for-profit R&D organization formed by the Drugs for Neglected Disease initiative (DNDi) and World Health Organization (WHO). It focusses on the promotion of public-private partnerships for increasing R&D of new antimicrobial diagnostics and agents.

Market Segmentation:

Based on Generation, the cephalosporin drugs market is segmented into first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin. Based on the application, the market is segregated into respiratory tract infection, skin infection, ear infection, sexually transmitted infection, and others. Based on the route of administration, the market is bifurcated into injections and oral drugs. Based on type, the market is divided into branded and generic. Geographic breakdown and analysis of each of the aforesaid segments includes regions comprising North America, Europe, Asia-Pacific, and RoW.

Market Dynamics and Factors:

The major factors contributing to the growth of the cephalosporin drugs market include an increase in the percentage of the population suffering from pneumonia, tonsillitis, bronchitis, and gonorrhea. In addition, an increase in R&D activities to develop highly efficient & safe drugs and an upsurge in the use of combination therapies has boosted the market growth. However, side effects associated with cephalosporin and the development of drug-resistant bacterial strains have restrained market growth. Furthermore, increasing demand for the antibacterial drives the global cephalosporin drugs market to grow further.

Geographic Analysis:

The global cephalosporin drugs market is expected to grow largely due to increasing demand for anti-microbial in various evidence, rising research and development activities, growing awareness among patients, increasing prevalence of infectious diseases, and special regulatory designation for pipeline molecule. India and China collectively contributed to more than 40% share of the Asia-Pacific cephalosporin market in 2017. The respiratory tract infection segment generated the highest revenue in 2017 and is anticipated to maintain its dominance throughout the forecast period, as cephalosporin is used for the treatment of both upper & lower respiratory tract infections and lower respiratory infections are the leading infectious causes of death globally.

Competitive Scenario:

The key players in the market are ABBOTT Laboratories, Teva Pharmaceuticals Industries Ltd., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer Inc., Merck & Co. Inc., Bayer AG, Baxter International Inc., Bristol-Myers Squibb Company, Novartis AG, Astellas, Roche, Bristol-Myers Squibb, Lupin Pharmaceuticals, Ranbaxy, Sandoz, and Teva Pharmaceuticals.

Cephalosporin Drugs Market Report Scope